Eliem Therapeutics (ELYM)
(Delayed Data from NSDQ)
$8.65 USD
-0.25 (-2.81%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $8.64 -0.01 (-0.12%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELYM 8.65 -0.25(-2.81%)
Will ELYM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELYM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELYM
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
ELYM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELYM
Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells Shares
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...
EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)
Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...